| Outcome Measures: |
Primary: Number of bowel movements, Changes from baseline in the number of completely spontaneous bowel movements (CSBMs) and number of spontaneous bowel movements (SBMs). Effectiveness is defined as CSBMs more than 3 times weekly (including 3 times) with increase from baseline, while ineffectiveness is defined as CSBMs less than 3 times weekly or with no increase from baseline., Baseline, Week 2, Week 4, Week 8, Week 12, Week 16|Glycosylated hemoglobin, Changes from baseline in glycosylated hemoglobin., Baseline, Week 12, Week 16|Glycosylated albumin, Changes from baseline in glycosylated albumin., Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 | Secondary: Gut micobiota, Changes from baseline in gut microbiota., Baseline, Week 4, Week 8, Week 12, Week 16|The ratio of CSBMs to SBMs, Changes from baseline in the ratio of CSBMs to SBMs., Baseline, Week 2, Week 4, Week 8, Week 12, Week 16|Bristol Stool Scale, Proportions whose stool characters recover to Type III and IV by Bristol Stool Scale., Baseline, Week 2, Week 4, Week 8, Week 12, Week 16|Bowel Function Index (BFI), Changes from baseline in the score of Bowel Function Index (BFI)., Baseline, Week 2, Week 4, Week 8, Week 12, Week 16|Patient Assessment of Constipation symptom (PAC-SYM), Changes from baseline in the scale of Patient Assessment of Constipation symptom (PAC-SYM)., Baseline, Week 2, Week 4, Week 8, Week 12, Week 16|Patient global impression of changes (PGIC), Difference in the Patient global impression of changes (PGIC) between experimental group and control group., Week 16|The first time of CSBM, Difference in the first time of completely spontaneous bowel movement (CSBM) between the experimental group and control group., Week 1 to Week 16|Fasting blood glucose, Changes from baseline in fasting blood glucose., Baseline, Week 2, Week 4, Week 8, Week 12, Week 16|Serum lipid spectrum, Changes from baseline in serum lipid spectrum., Baseline, Week 12
|
